tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia

Official title

Efficacy and Auditory Biomarker Analysis of Fronto-Temporal Transcranial Direct Current Stimulation (tDCS) in Targeting Cognitive Impairment Associated With Recent-onset Schizophrenia: A Randomized Double-blind Sham-controlled Trial

Overview

Background: In parallel to the traditional symptomatology, deficits in cognition (memory, attention, reasoning, social functioning) contribute significantly to disability and suffering in individuals with schizophrenia. Cognitive deficits have been closely linked to alterations in early auditory processes (EAP) that occur in auditory cortical areas. Preliminary evidence indicates that cognitive deficits in schizophrenia can be improved with a reliable and safe non-invasive brain stimulation technique called tDCS (transcranial Direct Current Stimulation). However, a significant proportion of patients derive no cognitive benefits after tDCS treatment. Further, the neurobiological mechanisms of cognitive changes after tDCS have been poorly explored in trials and are thus still unclear. Method: The study is designed as a randomized, double-blind, 2-arm parallel-group, sham controlled, 4-centers trial. Sixty participants with recent-onset schizophrenia and cognitive impairment will be randomly allocated to receive either active (n=30) or sham (n=30) tDCS (20-min, 2-mA, 10 sessions during 5 consecutive weekdays). The anode will be placed over the left dorsolateral prefrontal cortex and the cathode over the left auditory cortex. Cognition, tolerance, symptoms, general outcome and EAP (measured with EEG and multimodal MRI) will be assessed prior to tDCS (baseline), after the 10 sessions, and at 1- and 3-month follow-up. The primary outcome will be the number of responders, defined as participants demonstrating a cognitive improvement ≥Z=0.5 from baseline on the MATRICS Consensus Cognitive Battery total score at 1-month follow-up. Additionally, we will measure how differences in EAP modulate individual cognitive benefits from active tDCS and whether there are changes in EAP measures in responders after active tDCS. Discussion: Besides proposing a new fronto-temporal tDCS protocol by targeting the auditory cortical areas, we aim to conduct an RCT with follow-up assessments up to 3-months and a large sample size. In addition, this study will allow identifying and assessing the value of a wide range of neurobiological EAP measures for predicting and explaining cognitive deficits improvement after tDCS. The results of this trial will constitute a step toward the use of tDCS as a therapeutic tool for the treatment of cognitive impairment in recent-onset schizophrenia.

Interventions

• Device left fronto-temporal transcranial Direct Current Stimulation (tDCS)
  The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at "rest", comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrod

Primary outcome measures

• Cognitive response [Time frame: at 1-month follow-up]

Secondary outcome measures (12)

• Long term cognitive response [Time frame: at inclusion; at 3-months follow-up]
• Cognitive domain response [Time frame: at inclusion; at 1-month follow-up; at 3-months follow-up]
• Clinical response 1 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 2 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 3 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 4 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 5 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 6 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Clinical response 7 [Time frame: at inclusion; at 1-week; at 1-month follow-up; at 3-months follow-up]
• Outcome response 1 [Time frame: at inclusion; at 1-month follow-up; at 3-months follow-up]
• Outcome response 2 [Time frame: at inclusion; at 1-month follow-up; at 3-months follow-up]
• Tolerance 1 [Time frame: at 1-week]

Eligibility criteria

The inclusion criteria include:

• subjects of both genders, diagnosed with recent-onset schizophrenia (first 3 years of illness), confirmed through the Structured Clinical Interview for the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition (SCID-5);
• aged 18-35 years;
• intelligence quotient (IQ) > 55;
• cognitive deficit confirmed by a MCCB (MATRICS Cognitive Consensus Battery) total score T-score < 40;
• the subjects should be receiving stable doses of antipsychotics for ≥ 4 weeks;
• the subjects are covered by a public health insurance.

The exclusion criteria include:

• pregnant (controlled by urine pregnancy test in females of childbearing age) or breastfeeding women;
• unstable or acute medical conditions;
• subjects who receive involuntary treatment or guardianship;
• history of cranioencephalic trauma with loss of consciousness or central nervous system diseases that affect the brain;
• use of drugs that affect cognitive performance such as anticholinergic agents and benzodiazepines;
• current diagnosis of substance abuse or history of substance dependence in the last 6 months, except nicotine;
• MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) or tDCS (transcranial Direct Current Stimulation) contraindications

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

France · 4 centers

• CHU Grenoble Alpes — La Tronche
• CH Alpes-Isère — Saint-Égrève
• CH Le Vinatier — Bron
• CHU Saint-Etienne — Saint-Etienne

Publications

• Donde C, Bastin J, Pouchon A, Costes N, Fakra E, Galvao F, Gay A, Haesebaert F, Lamalle L, Merida I, Rigon M, Schneider F, Tropres I, Brunelin J, Polosan M. Efficacy and auditory biomarker analysis of fronto-temporal transcranial direct current stimulation (tDCS) in targeting cognitive impairment associated with recent-onset schizophrenia: study protocol for a multicenter randomized double-blind s PMID 36829240

Identifiers

NCT: NCT05440955 · STICOG

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗